61 related articles for article (PubMed ID: 299228)
1. [Serum ferritin in patients with malignant melanoma].
Linkesch W; Luger T; Kokoschka EM
Acta Med Austriaca Suppl; 1979; 6():346-9. PubMed ID: 299228
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous measurement of circulating intercellular adhesion molecule-1 and serum copper zinc superoxide dismutase activity in patients with malignant melanoma.
Wollina U; Karte K; Olbertz K; Hipler UC
Oncol Rep; 1998; 5(2):473-6. PubMed ID: 9468582
[TBL] [Abstract][Full Text] [Related]
3. Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR.
Mühlbauer M; Langenbach N; Stolz W; Hein R; Landthaler M; Buettner R; Bosserhoff AK
Clin Cancer Res; 1999 May; 5(5):1099-105. PubMed ID: 10353744
[TBL] [Abstract][Full Text] [Related]
4. [Relationship of serum iron and ferritin with the indicators for hepatic fibrosis].
Huang CW; Bai L; Cai JJ; Guo W; Lan L
Di Yi Jun Yi Da Xue Xue Bao; 2003 May; 23(5):466-8. PubMed ID: 12754132
[TBL] [Abstract][Full Text] [Related]
5. Serial determination of serum ferritin levels in patients with malignant melanoma.
Luger TA; Linkesch W; Knobler R; Kokoschka EM
Oncology; 1983; 40(4):263-7. PubMed ID: 6866423
[TBL] [Abstract][Full Text] [Related]
6. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma.
Abraha HD; Fuller LC; Du Vivier AW; Higgins EM; Sherwood RA
Br J Dermatol; 1997 Sep; 137(3):381-5. PubMed ID: 9349333
[TBL] [Abstract][Full Text] [Related]
7. MIA as a reliable tumor marker in the serum of patients with malignant melanoma.
Stahlecker J; Gauger A; Bosserhoff A; Büttner R; Ring J; Hein R
Anticancer Res; 2000; 20(6D):5041-4. PubMed ID: 11326664
[TBL] [Abstract][Full Text] [Related]
8. Circulating vascular endothelial growth factor in cutaneous malignant melanoma.
Pelletier F; Bermont L; Puzenat E; Blanc D; Cairey-Remonnay S; Mougin C; Laurent R; Humbert P; Aubin F
Br J Dermatol; 2005 Apr; 152(4):685-9. PubMed ID: 15840099
[TBL] [Abstract][Full Text] [Related]
9. [Serum ferritin in renal insufficiency, hemodialysis and kidney transplantation].
Hofmann V; Descoeudres C; Montandon A; Galeazzi RL; Straub PW
Schweiz Med Wochenschr; 1978 Nov; 108(47):1835-8. PubMed ID: 362527
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma.
Ghossein RA; Coit D; Brennan M; Zhang ZF; Wang Y; Bhattacharya S; Houghton A; Rosai J
Clin Cancer Res; 1998 Feb; 4(2):419-28. PubMed ID: 9516931
[TBL] [Abstract][Full Text] [Related]
11. High plasma proteasome levels are detected in patients with metastatic malignant melanoma.
Stoebner PE; Lavabre-Bertrand T; Henry L; Guiraud I; Carillo S; Dandurand M; Joujoux JM; Bureau JP; Meunier L
Br J Dermatol; 2005 May; 152(5):948-53. PubMed ID: 15888151
[TBL] [Abstract][Full Text] [Related]
12. Value of serum S-100B for prediction of distant relapse and survival in stage III B/C melanoma.
Smit LH; Nieweg OE; Mooi WJ; Bonfrer JM; Haanen JB; Kroon BB; De Gast GC
Anticancer Res; 2008; 28(4C):2297-302. PubMed ID: 18751409
[TBL] [Abstract][Full Text] [Related]
13. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
14. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.
Bosserhoff AK; Kaufmann M; Kaluza B; Bartke I; Zirngibl H; Hein R; Stolz W; Buettner R
Cancer Res; 1997 Aug; 57(15):3149-53. PubMed ID: 9242442
[TBL] [Abstract][Full Text] [Related]
15. [Serum S100B protein and stage of cutaneous melanoma: a prospective study].
Brouard M; Quillien V; Ollivier I; Lesimple T; Adamski H; Chevrant-Breton J
Ann Dermatol Venereol; 2000 Jan; 127(1):56-9. PubMed ID: 10717564
[TBL] [Abstract][Full Text] [Related]
16. [Survival analysis in patients with cutaneous malignant melanoma].
Radović-Kovacević V; Pekmezović T; Adanja B; Jarebinski M; Marinković J; Tomin R
Srp Arh Celok Lek; 1997; 125(5-6):132-7. PubMed ID: 9265233
[TBL] [Abstract][Full Text] [Related]
17. [Serum ferritin and iron therapy in patients treated with periodic hemodialysis].
Docci D; Cenciotti L; Turci F; Salvi G; Mosconi G; Baldrati L
Quad Sclavo Diagn; 1982 Dec; 18(4):454-62. PubMed ID: 7186648
[TBL] [Abstract][Full Text] [Related]
18. Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors.
Proebstle TM; Jiang W; Högel J; Keilholz U; Weber L; Voit C
Br J Cancer; 2000 Jan; 82(1):118-23. PubMed ID: 10638977
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma.
Hofmann MA; Gussmann F; Fritsche A; Biesold S; Schicke B; Küchler I; Voit C; Trefzer U
Melanoma Res; 2009 Feb; 19(1):17-23. PubMed ID: 19104451
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of tyrosinase mRNA detected by nested RT-PCR in patients with malignant melanoma.
Glumac N; Snoj M; Hocevar M; Novakovic S
Neoplasma; 2006; 53(1):9-14. PubMed ID: 16416006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
